New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2012
16:09 EDTNVAXNovavax' Phase I RSV vaccine data published in Vaccine
Novavax today announced that the journal Vaccine has published the company's data from its 2011 Phase I clinical trial of its respiratory syncytial virus, RSV, fusion, F,recombinant nanoparticle vaccine candidate. The paper was authored by a team of researchers and clinicians at Novavax and Dr. Pedro Piedra of Baylor College of Medicine. Findings from the trial were announced in October 2011 and presented in September by Novavax at the Respiratory Virus Symposium,RSV 2012, meeting in Santa Fe, New Mexico.
News For NVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
15:40 EDTNVAXJ&J deal for Alios sets valuation benchmark for Novavax, says Piper Jaffray
Subscribe for More Information
12:03 EDTNVAXAchillion sinks after Johnson & Johnson buys competitor
The shares of Achillion (ACHN), which has developed a treatment for hepatitis C based on a nucleotide and has been viewed as a potential takeover target by analysts previously, are falling after Johnson & Johnson (JNJ) announced this morning that it had agreed to acquire privately held Alios Biopharma. Alios has developed a number of nucleotide-based hepatitis C treatments, as well as an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus. WHAT'S NEW: Johnson & Johnson said that it had agreed to buy Alios for $1.75B. Alios has developed a number of nucleotides that could be used to treat hepatitis C virus, or HCV. Gilead's (GILD) popular HCV treatment Sovaldi is also a nucleotide and Achillion is developing its own HCV nucleotide treatment. According to The Street's Adam Feuerstein, Achillion's nucleotide is similar in structure to that of Alios. Johnson & Johnson had previously been rumored to be interested in buying Achillion, Feuerstein noted. WHAT'S NOTABLE: Johnson & Johnson said it was "excited" that its acquisition of Alios would enable it to "explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy." Novavax (NVAX) is also developing an RSV vaccine and Johnson & Johnson could have considered acquiring it before buying Alios, Feuerstein contended. PRICE ACTION: Near noon, Achillion fell 6% to $10.11, Gilead was down 0.6% to $106.84, Novavax dropped 1% to $4.27, and Johnson & Johnson rose 0.4% to just under $107 per share.
10:30 EDTNVAXJ&J could have considered Novavax, Achillion instead of Alios, TheStreet says
Subscribe for More Information
September 24, 2014
06:31 EDTNVAXNovavax price target raised to $10.50 from $9 at Piper Jaffray
Subscribe for More Information
September 23, 2014
12:33 EDTNVAXNovavax strong data validates purchase of Isconova, says Ladenburg
Subscribe for More Information
08:47 EDTNVAXNovavax announces BARDA exercise of contract option
Subscribe for More Information
08:41 EDTNVAXNovavax H7N9 vaccine candidate delivers positive Phase 1/2 clinical data
Novavax announced positive top-line data from a Phase 1/2 clinical trial of its H7N9 Avian Influenza VLP Vaccine Candidate, or H7N9 VLP, with proprietary adjuvant Matrix-M. This trial was conducted under the company's contract with HHS-BARDA for the development of VLPs to address influenza strains with pandemic potential. The H7N9 VLP, with and without Matrix-M, was well tolerated and demonstrated a safety profile similar to the company's prior experience with another saponin-based adjuvant. Matrix-M adjuvanted formulations demonstrated a clear immunogenicity benefit relative to unadjuvanted antigen, and a dose-response within the adjuvanted groups. Antigen dose-sparing was shown, such that even the 3.75g dose of antigen with either tested dose of adjuvant gave immune responses statistically significantly greater than 15g dose without adjuvant. Geometric mean titers of hemagglutination-inhibiting antibody after two vaccine doses were comparable to those reported in prior studies with another saponin adjuvant when similar antigen and adjuvant doses were compared. The vaccine also elicited anti-neuraminidase antibodies against N9, with 89 to 100% sero-response rates in the adjuvanted vaccine groups, and greater than 11-fold increases in geometric mean titers.
September 19, 2014
07:41 EDTNVAXNovavax coverage assumed with an Outperform at Wedbush
Subscribe for More Information
September 18, 2014
11:16 EDTNVAXNovavax to host analyst and investor day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use